India, July 17 -- Vanda Pharmaceuticals Inc. (VNDA) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for Imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis.
Understanding GPP
Generalized pustular psoriasis (GPP) is a severe, chronic, and potentially life-threatening inflammatory skin disease, genetically and clinically distinct from plaque psoriasis. It is driven by dysregulation in the interleukin-36 (IL-36) signaling pathway and is marked by widespread pustular eruptions, systemic inflammation, and serious complications that can lead to increased mortality.
Imsidolimab works by ...